CHICAGO, Jan. 24, 2018 -- To better reflect its expanded focus, Procured Health, the leading provider of data-driven analytics, evidence and expert guidance to help health systems cut costs and reduce unwarranted clinical variation, has changed its name to Lumere.
“We are pleased to announce this expanded focus and new name as the move toward value-based care accelerates,” said Hani Elias, JD, MPH, Chief Executive Officer of Lumere. “We formed Procured Health in 2012 to help hospitals and physicians make evidence-based, data-driven medical device selection and utilization decisions. We have since realized that the need for evidence-based medicine extends beyond device selection and that health systems are eager to support physicians in their quest to improve patient outcomes and performance. We have expanded our capabilities significantly to meet these needs and feel this new identity more accurately represents our expanded scope and mission.”
Lumere is backed by world-class healthcare investors including Heritage Group, FCA Ventures and F-Prime Capital Partners. The firm’s expanded focus includes added capabilities that address medication utilization and physician performance. The insights and recommendations are derived from a proprietary database that includes outcomes data and clinically-vetted benchmarks.
The company partners with over 60 health systems in more than 40 states and the United Kingdom. The goal is to ensure that care delivery choices are backed by data and guided by evidence, and drug and device costs are justified by clinical outcomes to make the best care decisions for every patient. This is achieved through the application of clinically focused information, analytics, technology and expertise.
“There is more data today than ever before to help doctors make decisions that improve outcomes and eliminate unnecessary costs,” said John Cherf, MD, MPH, MBA, Chief Medical Officer at Lumere. “It is our mission to leverage that data to effect change. We chose the name Lumere because it evokes an ideal state of enlightened healthcare where physicians can readily access unbiased, comprehensive insights to make cost-effective care delivery decisions.”
The most recent addition to Lumere’s solution suite was the launch of its web-based Pharmacy solutions that link a health system’s drug spend and utilization data to clinical evidence. In addition, the company has recently launched innovative professional services to support health systems seeking to provide dedicated performance improvement resources to physicians.
Aside from the name change, the company is making no other ownership or governance changes.
About Lumere
Lumere is at the forefront of clinical decision making for drugs and devices, offering evidence-based solutions and services for all providers that improve care and reduce cost across the patient journey. For more information, visit Lumere.com, find us on LinkedIn, follow @LumereHQ on Twitter and like us on Facebook.
Media Contacts
Pam Flores
[email protected]
773-218-9260


OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins
Samsung Electronics Shares Jump on HBM4 Mass Production Report
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances 



